Mergers and acquisitions are more than just exits for private biotech companies. They are the primary mechanism for returning capital to venture capitalists and LPs, who then reinvest those funds back into the ecosystem, fueling the next generation of innovative startups.

The medtech industry is uniquely squeezed by tariffs, inflation, and an inability to raise prices, crushing margins and valuations. This financial pressure has driven stock multiples to near all-time lows, signaling a major acquisition opportunity for private equity firms.

Years ago, MedTech M&A was driven by acquiring revenue and customer lists. Today, the priority has shifted to acquiring scarce, specialized technical capabilities and regulatory infrastructure that are difficult and time-consuming to build internally, signaling a major evolution in valuation drivers.

Increasing device complexity has outpaced the capabilities of most Original Equipment Manufacturers (OEMs). Advanced manufacturing platforms are now strategic assets, not just vendors, driving a shift in M&A focus from traditional devices to the organizations that can build them.

Over $22.8 billion from M&A deals in the first half of the year was returned to specialist biotech investors. This capital is being rapidly redeployed back into the sector, creating a significant tailwind that can explain otherwise news-free stock jumps in various biotech companies.

A confluence of factors is driving M&A toward Contract Development and Manufacturing Organizations (CDMOs). Capital is loosening as interest rates fall, a decade of private equity investments are maturing, pharma-device convergence (e.g., GLP-1s) is increasing, and geopolitical pressures encourage onshoring.

Private equity firms are again actively pursuing life sciences carve-outs and platform investments. Their characteristic speed and flexibility are pressuring corporate buyers, who now face increased competition and must adapt their own processes to compete effectively on deals.

Successful acquisitions don't just benefit the acquired company's investors. These investors often reinvest their profits into new, earlier-stage ventures, providing crucial capital that fuels the entire biotech ecosystem's growth and innovation.

The current M&A wave is unique because it includes both public and private company takeouts. This creates a robust capital recycling engine, providing quick returns to VCs (from private sales) and public specialist funds (from public takeouts). This capital is then immediately redeployed into new early and later-stage companies, sustaining the innovation ecosystem.